Brokerages predict that MediWound (NASDAQ:MDWD) will post $570,000.00 in sales for the current quarter, according to Zacks. Three analysts have provided estimates for MediWound’s earnings. The lowest sales estimate is $500,000.00 and the highest is $610,000.00. MediWound reported sales of $540,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 5.6%. The business is expected to issue its next earnings report on Monday, May 14th.
On average, analysts expect that MediWound will report full year sales of $3.66 million for the current year, with estimates ranging from $3.04 million to $4.05 million. For the next fiscal year, analysts anticipate that the company will post sales of $11.69 million per share, with estimates ranging from $5.80 million to $14.80 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow MediWound.
MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Monday, March 19th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.08. The company had revenue of $0.53 million during the quarter, compared to analysts’ expectations of $0.65 million. MediWound had a negative net margin of 887.38% and a negative return on equity of 234.12%.
MDWD has been the topic of a number of recent analyst reports. Wells Fargo cut their target price on shares of MediWound from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 20th. ValuEngine lowered shares of MediWound from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research lowered shares of MediWound from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Finally, Oppenheimer upped their target price on shares of MediWound from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, March 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. MediWound has an average rating of “Buy” and an average target price of $9.25.
NASDAQ:MDWD opened at $5.40 on Wednesday. The stock has a market capitalization of $146.06, a price-to-earnings ratio of -8.71 and a beta of -0.19. MediWound has a 1-year low of $3.56 and a 1-year high of $8.25.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Harel Insurance Investments & Financial Services Ltd. raised its stake in MediWound by 5,084.4% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 754,434 shares of the biopharmaceutical company’s stock worth $3,357,000 after acquiring an additional 739,882 shares during the period. Meitav Dash Investments Ltd. acquired a new stake in MediWound during the fourth quarter worth about $2,184,000. Nationwide Fund Advisors acquired a new stake in MediWound during the third quarter worth about $1,538,000. Wells Fargo & Company MN raised its stake in MediWound by 84.6% during the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 46,366 shares during the period. Finally, Renaissance Technologies LLC raised its stake in MediWound by 18.2% during the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the biopharmaceutical company’s stock worth $448,000 after acquiring an additional 15,500 shares during the period. Hedge funds and other institutional investors own 32.88% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/18/analysts-anticipate-mediwound-mdwd-will-post-quarterly-sales-of-570000-00.html.
MediWound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Get a free copy of the Zacks research report on MediWound (MDWD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.